Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration

SAN DIEGO and CAMBRIDGE, Mass., April 28 /PRNewswire/ -- ChemDiv, Inc.,
a global CRO for drug discovery & development, and Syndexa Pharmaceuticals
Corporation, a biopharmaceutical company developing first-in-class drugs
for the treatment of metabolic diseases, have announced today the signing
of a collaborative discovery research agreement. Under the terms of the
agreement, ChemDiv will discover small molecule ligands for biotargets
nominated by Syndexa. Financial terms of the collaboration were not
disclosed.

"We are very excited to deploy our discovery resources in this
collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at
ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery
of rapid, high-value results for our partners' drug discovery programs. We
are able to realize that goal through the creative integration of the
chemistry and biology components of our Discovery outSource(TM) platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery
partner with a strong track record. The collaboration will provide us with
access to high quality screening capabilities and compound library
resources. We anticipate that this project will accomplish our goal of
discovering promising drug leads to enhance our R&D pipeline," said Teo
Uysal, President and CEO, Syndexa Pharmaceuticals.

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global CRO delivering discovery
opportunities and services for life science partners. ChemDiv is merging
industrial and academic efforts to bring new approaches to the treatment of
life-threatening diseases. Drawing on a long heritage in small-molecule
chemistry research, a dedicated and personal approach to collaborative
research and development as well as world class personnel and physical
resources, ChemDiv provides partners with access to Discovery outSource(TM)
a full service drug discovery offering encompassing synthetic chemistry;
medicinal chemistry, diverse & focused screening libraries, global
logistics and wide range of biology services for pre-clinical discovery &
development projects. http://www.chemdiv.com

About Syndexa Pharmaceuticals Corporation:

Syndexa is engaged in the discovery and development of a new generation
of small-molecule drugs that target the biological interface between
inflammatory and metabolic pathways, and provide a novel mechanism for the
treatment and prevention of metabolic diseases including obesity, type 2
diabetes and atherosclerosis. Syndexa's current programs include the
development of inhibitors of obesity-induced Endoplasmic Reticulum (ER)
stress and c-jun N-terminal kinase (JNK). Founded by leading scientists
from Harvard and University of California, San Diego, the company is
executing on its business strategy to rapidly build and commercialize a
portfolio of breakthrough products. The company is headquartered in
Cambridge, MA. For additional information, please visit
http://www.syndexa.com.





See Also

• Martek to Present at Upcoming Deutsche Bank Conference
• Hahnemann University Hospital and St. Christopher's Hospital for Children Receive Prestigious Tenet Circle of Excellence Award
• Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
• SXC Health Solutions reports on the status of its bid for a PBM contract with a State Medicaid program

Via: Healthcare